An update on COVID-19 outbreak: The longest pandemic

Abstract

A novel epidemic case of coronavirus disease is an infectious disease caused by a newly discovered virus COVID-19, they are originated by some untraceable origin. Coronavirus belongs to a large family of viruses that may cause illness in animals or humans. They are known to cause respiratory infections starting from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS). The first transmission of the Corona virus was seen to humans in Wuhan, China. Since then, these viruses have mostly spread almost all over the world through person-to-person contact and mainly expanding in Europe, North America, Asia, and also in India. The irony is not much is known about this virus, hence mortality and morbidity across the globe are at a peak. The Ministry of Health and  Family Welfare, Government of India, and Indian Council of Medical Research (ICMR) have formulated some guidelines, advisories for social distancing protocol, diagnosis, management, do’s and don'ts, and other reliable material to break the chain of this viruses. The current article covers the introduction, history and background, origin and spread, possible mode of transmission, clinical features, symptoms, diagnosis and testing, treatment and management, role of antiviral and preventive measurement from COVID-19. This article may help readers to have the latest understanding of this new infectious disease.

References

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;714-20.
2. Su. S, Wong G, Shi W, Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiology 2016.
3. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019- nCoV) coronavirus. An J Respir Crit Care Med, 2020; 201-207.
4. World health organizations. Novel coronavirus-China. 2020. Accessed january 16, 2020 https://www.who.int/csr/don/12-january-2020 novel coronavirus china/en/.
5. Wuhan coronavirus (2019 nCov) global cases. 2020. https://gisanddata.maps.arcgis.co m/apps/opsdashboard/index.
6. WHO Coronavirus disease (Covid 2019) situation reports (2020). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
7. WHO Virtual press conference on COVID 19. https://www.who.int/docs/default sourc e/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full- and-final-11mar 2020.
8. Wu Z, Mc Googan JM. Characteristics of and important lessons from the corona virus disease 2019 (COVID 19) outbreak in China: summary of a report of 72314 case from the Chinese Centre for Disease Control and Prevention. JAMA 2020.
9. WHO Report of the WHO China Joint Mission on Coronavirus Disease 2019 (COVID 19). https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission- on-covid-19.
10. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China, the mystery and the miracle. J Med Virol.2020; 92:401-402. 10.1002/jmv.25678
11. Richman DD, Whitley RJ, Hayden FG. Clinical Virology, 4th edition. Washington, ASM Press; 2016.
12. Du Toit, An outbreak of a novel coronavirus. Nat Rev Microbiol. 2020; 18:123. 10.1038/s41579-020-0332-0
13. ChanYeung M, Xu RH, SARS: epidemiology. Respirology. 2003;8:S9–14.
14. Mishra S, Sharma D, Raghuvanshi A, Rajput A, Chaturvedi V, Shanno K. Potential Impact of Nutrition on Immune System: Prevent or Assist COVID-19 Recovery. Journal of Advances in Medicine and Medical Research. 2020;23:20-33.
15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients in- fected with 2019 novel corona virus in Wuhan, China. Lancet (London, England). 2020; 395:497-506.
16. Liu, Y., Gayle, AA. Wilder Smith, A., Rocklov, J. The reproductive number of Covid- 19 is higher compared to SARS corona virus. J Travel Med. 2020.
17. Singh Tanu. A review on corona virus disease-2019 (Covid -9). The Ind J paediatric, 2020;87: 281-286.
18. Seyed Alinaghi S, Mirzapour P, Dadras O. et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res. 2021; 26: 51.
19. Poterico JA, Mestanza O. Genetic variants and source of introduction of SARS-CoV-2 in South America. J Med Virol. 2020;10:2139–45.
20. Parlikar A, Kalia K, Sinha S, Patnaik S, Sharma N, Vemuri SG, et al. Understanding genomic diversity, pan-genome, and evolution of SARS-CoV-2. Peer J. 2020;8:e9576.
21. Pachetti M, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18:1–9.
22. Mukherjee M, Goswami S. Global cataloguing of variations in untranslated regions of viral genome and prediction of key host RNA binding protein-microRNA interactions modulating genome stability in SARS-CoV-2. PLoS ONE. 2020;15(8):e0237559.
23. Muhammad Ansori AN, Dhea Kharisma V, Sabilil Muttaqin S, Antonius Y, Parikesit AA. Genetic variant of SARS-CoV-2 isolates in Indonesia: spike glycoprotein gene. J Pure Appl Microbiol. 2020;14(1):971–8.
24. Lokman SM, Rasheduzzaman M, Salauddin A, Barua R, Tanzina AY, Rumi MH, et al. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein a computational biology approach. Infect Genet Evol. 2020;84:104389.
25. Lau S-Y, Wang P, Mok BW-Y, Zhang AJ, Chu H, Lee AC-Y, et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microb Infect. 2020;9(1):837–42.
26. Kozlovskaya L, Piniaeva A, Ignatyev G, Selivanov A, Shishova A, Kovpak A, et al. Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak. Int J Infect Dis. 2020;99:40–6.
27. Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ. 2020;98(7):495.
28. Bassetti, M., Vena, A., Giacobbe, DR., The novel Chinese coronavirus (2019 nCoV) infections, challenges for fighting the storm. Eur J Clin Invest. 50:e13209. 10.1111/eci.13209
29. Mishra Sudhanshu, Sharma Disha, Srivastava Prakash Shobhit, Verma Swati and Malviya Rishabha, Impact on Pharmaceutical Industry due to Sudden Pandemic Attack (COVID-19), Coronaviruses 2022; 3.
30. Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified corona virus may boost cross-species transmission from snake to human. Journal of medical virology.2020.
31. Zhang C, Zheng W, Huang X, Bell EW, Zhou X, Zhang Y. Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV 2020, 1.02.04.933135
32. Wang J, Zhao S, Liu M, Zhao Z, Xu Y, Wang, P. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. 2020: 02.05.20020545.
33. Xiao F, Tang M, Zheng X, Li C, He J, Hong Z. Evidence for gastrointesti- nal infection of SARS CoV 2.medRxiv.2020: 02.17.2002372.
34. Cho SY, Kang JM, Ha YE, Park GE, Lee JY, Ko JH, MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea, an epidemi ological outbreak study. Lancet 2016; 388:994-1001.
35. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incu- bation periods of acute respiratory viral infections: a systematic review. The Lancet Infectious diseases. 2009; 9:291-300.
36. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel Corona virus (2019-nCoV) in Wuhan, China. Journal of medical virology.2020: 92:441-7.
37. Guan W J, Ni ZY, Hu Y, Liang WH. Clinical characteristics of 2019 novel corona virus infection in China.2020; 02.06.20020974.
38. Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–13.
39. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, Characteristics of lymphocyte sub- sets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel corona virus pneumonia (NCP). Med Rxiv.2020; 02.10.20021832.
40. Sinha, A., One COVID-19 positive infects 1.7 in India, lower than in hot zones.The Indian Express, 23 March 2020.
41. Ren LL, Wang YM, Wu ZQ. Identification of a novel coronavirus causing severe pneumonia in human, a descriptive study. Chin Med J. 2020; 10.1097/CM9.
42. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W. Correlation of Chest CT and RT-PCR Testing in Corona virus Disease 2019 (Covid-19) in China. A Report of 1014 Cases. Radiology.2020; 200642
43. Li Z, Wu M, Guo J, Yao J, Liao X, Song S. Caution on Kidney Dysfunctions of 2019-nCoV Patients. 2020
44. Sharma K, Mishra S, Gautam A, Malviya R. Mucormycosis-a Fungal Infection in Patient Recovered from COVID-19.
45. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi. 2020; 58:E009.
46. PRC NH Cot, The Novel Corona virus Pneumonia Diagnosis and Treatment Plan 2020.
47. Huang P, Liu T, Huang L. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 2020; https://doi.org/10.1148/radiol.2020200330.
48. Guidelines on Clinical Management of Covid 19. Available from: https://www.mohfw.go v.in/pdf/Guidelines on Clinical Management of Covid- 19.
49. Lu H, Drug treatment options for the 2019, new coronavirus (2019-nCoV). Biosci Trends. 2020; 14:69-71. 10.5582/bst.2020.01020.
50. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70(7): 2129-3.
51. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653.
52. Saijo M, Morikawa S, Fukushi S, et al. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res 2005; 66(2-3): 159-63.
53. Peters HL, Jochmans D, de Wilde AH, et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg Med Chem Lett 2015; 25(15): 2923-6.
54. Shoemaker CJ, Schornberg KL, Delos SE, et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One 2013; 8(2): e56265.
55. Bleibtreu A, Jaureguiberry S, Houhou N, et al. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis 2018; 18(1): 331-40.
56. Al-Abdely HM, Midgley CM, Alkhamis AM, et al. Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. Emerg Infect Dis 2019; 25(4): 753-66.
57. Saeed AA, Abedi GR, Alzahrani AG, et al. Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015– February 2016. Emerg Infect Dis 2017; 23(4): 682-5.
58. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4-26.
59. Dayer MR, Taleb-Gassabi S, Dayer MS. Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. Arch Clin Infect Dis 2017; 12: e13823-30.
60. Ojha S, Chadha H and Jain S, COVID-19: Pathogenesis and Pharmacological Basis for Use of Passive Antibody Therapy, Current Drug Therapy. 2020;15 (5), 448-456.
61. Holshue ML, De Bolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H. First Case of 2019 Novel Corona virus in the United States. The New Eng J Med. 2020.
62. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. Remdesivir and Chloroquine effectively inhibit the recently emerged novel corona virus (2019-nCoV) in vitro. Cell Res.2020.
63. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antivi- ral compound that blocks viral fusion. Curr Med Chem.12008: 5:997-1005.
64. Polack FP. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383, 2603–2615.
65. Baden LR. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384: 403–416 (2021).
66. Kirby J. Israel outpaced the world in vaccinations. Now it’s seeing the results. Vox (2021). https://www.vox.com/22262509/israel-covid-19-vaccinations serious-illness-decline. 109.
67. Castells MC & Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N. Engl. J. Med. 2020;384, 643–649.
68. Jeyanathan M. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol.2020; 20, 615–632.
69. Voysey M. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet.2021; 397, 99–111.
70. Zhu FC. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395, 1845–1854.
71. Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507-513. 10.1016/S0140-6736(20)30211-7.
72. Cao B, Wang Y, Wen DA. Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med. 2020;10.1056/NEJMoa2001282.
73. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H. Interferonal- facon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Jama.2013; 290:3222-8.
74. Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune- modulating therapy. Cmaj. 2015; 187:257-64.
75. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstadt H. Effect of Early vs. Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury, The Elain Randomized Clinical Trial. Jama.2016.
76. Lim CC, Tan CS, Kaushik M, Tan HK. Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study. Nephrology Carlton.2015;20:148-54.